Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) CEO Michael A. Martino Buys 76,890 Shares

Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE – Get Rating) CEO Michael A. Martino bought 76,890 shares of the company’s stock in a transaction on Wednesday, May 24th. The shares were purchased at an average cost of $0.29 per share, for a total transaction of $22,298.10. Following the transaction, the chief executive officer now owns 76,890 shares in the company, valued at $22,298.10. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Ampio Pharmaceuticals Trading Up 6.4 %

Shares of NYSEAMERICAN:AMPE traded up $0.02 during mid-day trading on Friday, reaching $0.30. The company had a trading volume of 422,326 shares, compared to its average volume of 291,843. The firm has a market cap of $4.60 million, a price-to-earnings ratio of -0.15 and a beta of 1.48. The company’s 50-day moving average price is $0.24 and its 200-day moving average price is $0.26. Ampio Pharmaceuticals, Inc. has a one year low of $0.18 and a one year high of $3.94.

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE – Get Rating) last posted its quarterly earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter.

Institutional Investors Weigh In On Ampio Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Bank of Montreal Can bought a new position in Ampio Pharmaceuticals in the 1st quarter worth about $168,000. BlackRock Inc. boosted its stake in Ampio Pharmaceuticals by 0.4% in the 1st quarter. BlackRock Inc. now owns 13,996,074 shares of the specialty pharmaceutical company’s stock worth $6,578,000 after purchasing an additional 61,269 shares during the period. Vanguard Group Inc. boosted its stake in Ampio Pharmaceuticals by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 9,307,338 shares of the specialty pharmaceutical company’s stock worth $4,375,000 after purchasing an additional 77,822 shares during the period. State Street Corp boosted its stake in Ampio Pharmaceuticals by 2.0% in the 1st quarter. State Street Corp now owns 3,430,770 shares of the specialty pharmaceutical company’s stock worth $1,612,000 after purchasing an additional 66,375 shares during the period. Finally, Virtu Financial LLC bought a new position in Ampio Pharmaceuticals in the 2nd quarter worth about $72,000. Institutional investors own 19.82% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Ampio Pharmaceuticals in a research report on Saturday, May 20th. They set a “sell” rating on the stock.

Ampio Pharmaceuticals Company Profile

(Get Rating)

Ampio Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease.